This fact sheet highlights the involvement of the EU in the global land grab, both directly through the involvement of European capital and corporations in the acquisition of land and indirectly through EU policies that commodify land.
This study brings together available evidence to provide a comprehensive analysis of cannabis production and markets across the EU. It combines information from EMCDDA routine reporting — data on patterns of prevalence and use, seizures, police reports, drug-law offences, cannabis potency and retail market prices — with literature on cannabis markets to create an in-depth analysis of the issue in a European context.
El debate político sobre las drogas en América Latina está dando pasos notorios. Los cambios legislativos que están introduciendo varios de los países de la región revelan también una tendencia innegable a alejarse de la “guerra contra las drogas”. Este informe explica los antecedentes de la apertura del debate sobre las políticas de drogas en la región, resume los aspectos más relevantes de las reformas a las leyes de drogas que actualmente cursan en algunos países y propone una serie de recomendaciones de políticas que podrían ayudar a avanzar el debate de manera productiva.
Remarkable drug policy developments are taking place in Latin America. This is not only at the level of political debate, but is also reflected in actual legislative changes in a number of countries. All in all there is an undeniable regional trend of moving away from the ‘war on drugs’. This briefing explains the background to the opening of the drug policy debate in the region, summarises the most relevant aspects of the ongoing drug law reforms in some countries, and makes a series of recommendations that could help to move the debate forward in a productive manner.
The global war on drugs is driving the HIV pandemic among people who use drugs and their sexual partners. Throughout the world, research has consistently shown that repressive drug law enforcement practices force drug users away from public health services and into hidden environments where HIV risk becomes markedly elevated. Mass incarceration of nonviolent drug offenders also plays a major role in spreading the pandemic. Today, there are an estimated 33 million people worldwide living with HIV – and injection drug use accounts for one-third of new HIV infections outside of sub-Saharan Africa.
The Alternative World Drug Report, launched to coincide with publication of the UN Office on Drugs and Crime’s 2012 World Drug Report, exposes the failure of governments and the UN to assess the extraordinary costs of pursuing a global war on drugs, and calls for UN member states to meaningfully count these costs and explore all the alternatives.
La guerra global a las drogas está impulsando la pandemia del VIH entre las personas que usan drogas y sus parejas sexuales. En todo el mundo, la investigación científica ha demostrado consistentemente que las prácticas represivas de aplicación de ley de drogas distancian a los usuarios de drogas de los servicios de salud pública y los obliga a permanecer en entornos ocultos donde el riesgo del VIH se eleva notablemente. El encarcelamiento masivo de infractores no violentos a la ley de drogas también juega un papel importante en la diseminación de la pandemia. Hoy en día, se estima que 33 millones de personas en todo el mundo viven con el VIH, y las personas que se inyectan drogas representan aproximadamente la tercera parte de las nuevas infecciones de VIH que se producen fuera del África subsahariana.
As the debate on drug policy and law reform gathers momentum on the international stage, the failings of the three UN drug control conventions (1961, 1971 and 1988) have come into stark relief. Criticisms of the global drug control regime established by the drug treaties have now entered the mainstream public discourse and political debate. The discussions around treaty reform that would allow or facilitate a wider spectrum of approaches to drugs are assuming a degree of urgency.
Millions of dollars in international aid for drug enforcement is spent in countries with extremely poor human rights records and with little or no accountability for the resulting abuses, according to a this investigative report carried out by the UK-based drugs and human rights organisation, Harm Reduction International. The report tracks drug enforcement funding from donor states, often via the United Nations, to countries where executions, arbitrary detention, physical abuse and slave labour are weapons in the war on drugs.
For the past 10 to 20 years, drug consumption rooms (DCRs) have become an integrated part of the drug treatment and harm reduction strategy in a variety of countries in Western Europe, North America and Australia. However, they have not yet been established in the majority of countries worldwide.
The European Commission's promotion of 'bioeconomies' as a central focus at Rio+20 is more about protecting banking, biotech, manufacturing, agribusiness and energy sectors then defending vulnerable communities and the environment.
Proportionality is one of the key principles of the rule of law aiming to protect people from cruel or inhumane treatment. The principle has been established in international and regional human rights agreements and many countries have adopted reflections of it in their constitution or penal code. Its application to drug-related offences is firstly the responsibility of the legislators, in defining the level of penalisation of certain behaviours. The level of penalisation should be determined according to the severity of damage that a certain behaviour causes to others or to society.
Este número especial de “América Latina en Movimiento” de ALAI muestra el funcionamiento del capital transnacional, los sectores en los que actúa, su lógica globalizada, la estructura de su promiscua relación con los poderes públicos a todos los niveles, la magnitud de los abusos y su irresponsabilidad social, económica y ambiental.
How does transnational capital function? Where does it operate? What globalised logic does it follow? What is the magnitude of its abuses and its social, economic and environmental irresponsibility? And what challenge do we see emerge for us, the people?
The people of Burma are at a critical juncture in their struggle for democracy and ethnic reform. Decisions taken by leading parties and protagonists in the months ahead could well define the direction of national politics for many years to come.
There is a growing body of evidence to support the use of medical cannabis as an adjunct to or substitute for prescription opiates in the treatment of chronic pain. When used in conjunction with opiates, cannabinoids lead to a greater cumulative relief of pain, resulting in a reduction in the use of opiates (and associated side-effects) by patients in a clinical setting. Additionally, cannabinoids can prevent the development of tolerance to and withdrawal from opiates, and can even rekindle opiate analgesia after a prior dosage has become ineffective.
La proporcionalidad es uno de los principios fundamentales del Estado de derecho para proteger a las personas de tratos crueles e inhumanos. El principio está establecido en acuerdos internacionales y regionales sobre derechos humanos, y muchos países han adoptado observaciones al respecto en su constitución o código penal. Su aplicación en delitos relacionados con drogas depende, en primer lugar, de los responsables de la legislación, puesto que ellos son los encargados de definir el nivel de penalización de determinadas conductas.
The seminar entitled “Modernising the global drug control system – Can Europe lead?” was organised in the European Parliament by the International Drug Policy Consortium (IDPC), and the Global Commission on Drug Policy, and co-hosted by the Member of European Parliament (MEP) Nikos Chrysogelos. The event aimed to present the recommendations of the Global Commission and discuss the role that the European Union (EU) could play in current drug policy reform debates taking place within Europe and around the world. The seminar also comes at a time when the EU is working on drafting a new Drug Strategy to replace the one that will expire at the end of 2012.